Leadership: Page 4
-
Maddie Meyer via Getty Images
Q&AFor Moderna, COVID vaccines were a ‘proof of concept’ — now comes the big test
Following Moderna’s COVID-19 vaccine success, therapeutics head Dr. Kyle Holen discusses scaling mRNA development to bring candidates to the finish line in oncology and more.
By Amy Baxter • Feb. 23, 2024 -
Win McNamee via Getty Images
AbbVie CEO Richard Gonzalez leaves a divisive Humira legacy and lasting impact on pharma
Leading AbbVie to become one of the most successful pharmas in the world, Gonzalez also rubbed some critics the wrong way.
By Michael Gibney • Feb. 22, 2024 -
Explore the Trendline➔
Stock via Getty Images
TrendlineCommercialization, marketing and social media
As the pharma industry stares down a historic patent cliff, macroeconomic headwinds and challenging R&D costs for increasingly complex medicines, nailing the launch of new medicines has become increasingly critical.
By PharmaVoice staff -
Chip Somodevilla/Getty Images via Getty Images
Biden or Trump: How deeply will 2024’s election outcome impact pharma?
The election is still months away, but campaign promises are solidifying, and signal the benefits and drawbacks of each candidate for pharma.
By Michael Gibney • Feb. 20, 2024 -
Stock via Getty Images
Pharma CFOs need R&D vigilance in tough economic times
Belt tightening and streamlined portfolios are critical in 2024 amid continued economic uncertainty.
By Amy Baxter • Feb. 16, 2024 -
Courtesy of Biogen
The roadblocks faced by Biogen are many, but execs point to an R&D-focused turnaround
A disappointing few years for Biogen have led leadership to use new drug launches as fuel for an about-face.
By Michael Gibney • Feb. 15, 2024 -
Permission granted by Pfizer
‘I wish I could see the end of the day’ — a Pfizer exec on the fight for health equity
The pharma giant’s leader of a collective devoted to health equity discusses how companies can put their money where their mouth is to reach communities in need.
By Michael Gibney • Feb. 14, 2024 -
Win McNamee via Getty Images
FDA inches closer to defining its regulatory role in AI
Commissioner Dr. Robert Califf signals how the FDA will consider AI in drug development and how the agency may use the emerging technology in the future.
By Amy Baxter • Feb. 12, 2024 -
iStock via Getty Images
Big Pharma players Amgen, Roche and Pfizer seek to follow in Novo and Lilly’s weight loss footsteps
While Novo Nordisk and Eli Lilly have a sizable lead in the quickly expanding GLP-1 market, Big Pharma peers are looking for a way in.
By Michael Gibney • Feb. 8, 2024 -
Permission granted by Mural Oncology
Q&AWhy a former BMS exec calls her new CEO role ‘unfinished business’ in cancer care
With a focus on her “three pillars” of being a CEO, Caroline Loew explains how she’s building a new company culture at an Alkermes spinoff — and a pipeline that offers a next-gen approach to oncology.
By Alexandra Pecci • Feb. 6, 2024 -
Stock via Getty Images
Vaxxinity is brewing up meds for a spacefaring future
The biotech’s bone- and muscle-building treatments could someday help humans reach other planets.
By Kelly Bilodeau • Feb. 5, 2024 -
Marko Georgiev / Stringer via Getty Images
Merck keeps deal focus with Keytruda patent cliff on horizon
The company is open to deals the size of its prior Acceleron and Prometheus buyouts. “We continue to believe we need more,” CEO Rob Davis said.
By Ned Pagliarulo • Feb. 1, 2024 -
Drew Angerer via Getty Images
Pfizer’s COVID vax and antiviral sales have crashed. Will the ‘big bet’ on Seagen even the keel?
In the first earnings call since the $43 billion Seagen deal closed, CEO Albert Bourla stressed that Pfizer is all in on the promise of ADCs to make up for COVID losses.
By Michael Gibney • Feb. 1, 2024 -
Permission granted by City of Hope
Immunotherapy changed the cancer treatment landscape. Is the gut microbiome the next frontier?
The president of L.A.’s City of Hope Cancer Center believes the current state of cancer treatments can be greatly improved with a peek into the gut’s many mysteries.
By Michael Gibney • Jan. 31, 2024 -
Permission granted by Amylyx
Q&A‘1 plus 1 equals 3’ — the co-CEO model in pharma
Amylyx Pharmaceuticals’ co-founders and co-CEOs Josh Cohen and Justin Klee explain their approach to dual leadership and why it can be a good fit in life sciences.
By Meagan Parrish • Jan. 26, 2024 -
Stock via Getty Images
The biggest questions hanging over pharma in 2024
Key trends on the horizon in the life sciences this year.
By Meagan Parrish • Jan. 25, 2024 -
Mike Coppola via Getty Images
J&J’s 2024 strategy will focus on newer meds to offset Stelara’s patent cliff
Executives on the healthcare giant’s full-year earnings call highlighted a strong cash position and incremental dealmaking as a way to get past incoming competition.
By Michael Gibney • Jan. 24, 2024 -
Permission granted by Takeda Pharmaceuticals
Five years after closing the Shire deal, Takeda is ready to harvest from its latest reinvention
Amid criticisms of Takeda’s megamerger, the company’s CSO said it has built a pipeline that will deliver.
By Meagan Parrish • Jan. 19, 2024 -
Kevin Dietsch via Getty Images
FDA chief says agency can’t manage health tech alone
FDA Commissioner Dr. Robert Califf recently spoke about the future of AI and machine learning and the need for constant vigilance to improve healthcare systems.
By Alexandra Pecci • Jan. 16, 2024 -
Stock via Getty Images
OpinionPharma execs sound off on trends and policies they’re tracking in 2024
From regulatory concerns to leadership skills, pharma leaders at JPM shared how they’re approaching the coming year.
By Meagan Parrish • Jan. 12, 2024 -
Stock via Getty Images
10 of our most read articles in 2023
A presidential candidate, a changing biotech market and an enduring murder mystery — here are PharmaVoice’s most-read articles this year.
By Meagan Parrish • Dec. 22, 2023 -
Permission granted by Roivant
ProfileRise of the chief investment officer: Why the unique role works for Roivant
Dr. Mayukh Sukhatme, president and chief investment officer for Roivant, discusses the long game of partnering and business deals in biopharma.
By Alexandra Pecci • Dec. 18, 2023 -
Permission granted by FNIH
Q&AA former CDC head on key R&D areas, public trust and if we learned anything from COVID-19
Dr. Julie Gerberding, now president and CEO of the Foundation for the National Institutes of Health, shares lessons learned from a long career in academic, public health and industry.
By Meagan Parrish • Dec. 13, 2023 -
Permission granted by Adam Lenkowsky
Q&ABristol Myers’ commercial chief on the industry’s ‘seismic’ changes over 27 years and what’s coming next
Adam Lenkowsky’s unique vantage point on the major transformations shaping BMS and the industry as a whole.
By Michael Gibney • Dec. 12, 2023 -
Permission granted by Real Chemistry
Real Chemistry’s CEO on biopharma’s outlook in 2024
Shankar Narayanan, CEO of marketing consulting firm Real Chemistry, weighs in on where the industry is headed in the New Year.
By Michael Gibney • Dec. 7, 2023 -
Amicus Therapeutics
BIO names longtime Amicus head John Crowley as new CEO
Crowley, a rare disease advocate who led Amicus for nearly two decades, will take the reins as the industry group seeks to challenge Medicare’s new drug pricing powers.
By Jonathan Gardner • Dec. 5, 2023
Previous
